A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).
Ian Flinn
Research Funding - Gilead Sciences
Eva Kimby
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Finbarr E. Cotter
Research Funding - Gilead Sciences
Francis J. Giles
Research Funding - Gilead Sciences
Ann Janssens
Research Funding - Gilead Sciences
Elisa Jacobsen Pulczynski
No relevant relationships to disclose
Loic Ysebeart
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Andrzej Pluta
Research Funding - Gilead Sciences
Jose Antonio Garcia Marco
Research Funding - Gilead Sciences
Kerry Taylor
Research Funding - Gilead Sciences
Carolyn Owen
Research Funding - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Maria Aiello
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Ronald L. Dubowy
Employment or Leadership Position - Gilead Sciences
Jeffrey Alan Jones
Research Funding - Gilead Sciences